Boston Children’s Hospital has patented a method for analyzing somatic mutations in mitochondrial DNA to infer cell lineages and clonal structures in single cells. This approach utilizes contemporary genomic technologies to track mutations and assess gene expression and chromatin accessibility in complex cellular populations. GlobalData’s report on Boston Children’s Hospital gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Boston Children's Hospital, was a key innovation area identified from patents. Boston Children's Hospital's grant share as of June 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Method for inferring cell lineages using mitochondrial mutations
The granted patent US12012633B2 outlines a method for determining the lineage and clonal structure of single cells within multicellular eukaryotic organisms, particularly focusing on the analysis of mitochondrial genome mutations. The method involves detecting mutations in mitochondrial genome sequencing reads from single cells obtained from a subject and clustering these cells based on the identified mutations. This process allows for the retrospective inference of lineage and clonal structures. The claims further specify that the method may include sequencing mitochondrial genomes, detecting mutations with a minimum threshold of heteroplasmy, and utilizing both single-cell and bulk sample analyses to enhance the accuracy of mutation detection.
Additionally, the patent describes applications of this method in cancer research, including identifying clonal populations in tumor samples and determining therapeutic targets based on differential cell states among these populations. The claims encompass various techniques such as single-cell RNA sequencing (scRNA-seq) and single-cell ATAC-seq (scATAC-seq) to analyze both mitochondrial and nuclear genomes. The methodology also allows for the comparison of clonal populations between healthy and diseased tissues, potentially aiding in the development of targeted cancer treatments. Overall, the patent presents a comprehensive approach to understanding cellular lineage and clonal dynamics, with significant implications for cancer diagnostics and therapeutics.
To know more about GlobalData’s detailed insights on Boston Children's Hospital, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
